Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 7050 participants.
Also called NCT07318610
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 7,050 participants
- Sponsor
- Registry
-
NCT07318610 -
2025-522954-37-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Japan, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07318610. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-10 (actual); primary completion 2029-08-18 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
- Acronym
- ROXI-PALISADE
- Condition
- Peripheral Artery Disease (PAD)
- Intervention (Drug)
- REGN7508
- Intervention (Drug)
- REGN9933
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Rivaroxaban
- Lead sponsor
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct07318610- Content hash
653bef5660ed60f380a4fd5c1a7348562113a179905295651832551f641a5a17